Royal Bank Of Canada Rubius Therapeutics, Inc. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.14 - $0.31 $63 - $141	-456 Reduced 99.35%	3 $0
Q3 2022 Nov 14, 2022	BUY	$0.46 - $1.29 $211 - $592	459 New	459 $0
Q2 2022 Aug 15, 2022	SELL	$0.79 - $5.98 $2,229 - $16,875	-2,822 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.25 - $10.4 $2,392 - $5,855	-563 Reduced 16.63%	2,822 $16,000
Q4 2021 Feb 14, 2022	BUY	$9.68 - $17.74 $32,766 - $60,049	3,385 New	3,385 $33,000
Q3 2021 Nov 15, 2021	SELL	$17.6 - $25.91 $54,331 - $79,984	-3,087 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$22.26 - $28.43 $68,716 - $87,763	3,087 New	3,087 $75,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.